Skip to main content
TipRanks
Go Ultimate75% OFF

Symbio Pharmaceuticals Limited (4582) AI Stock Analysis

1 Followers
JP:4582

Symbio Pharmaceuticals Limited

(TSE/TYO:4582)

Select Model
Rating:37Underperform
Price Target:JPY 73.00â–²(5.80% Upside)
Action:downgraded
Date:11/20/26

The score is driven overwhelmingly by severe financial deterioration: collapsing revenue, a ¥4.8B net loss, -¥4.6B operating cash flow that exceeds remaining equity, and newly added debt against a shrinking balance sheet point to liquidity risk and possible dilutive financing or restructuring. Valuation offers no cushion, with negative earnings and no dividend. The only offsetting factor is near-term technical strength, with the price trading above its 20-, 50- and 100-day averages on positive MACD momentum, though it remains below the 200-day average. On balance, the speculative risk profile outweighs the recent price recovery.

Positive Factors
High gross marginA high gross margin indicates that the company’s products can retain meaningful value after direct production costs. If operating expenses become better aligned with revenue, this underlying economics could support margin recovery, although current losses show that improvement is not yet established.
Negative Factors
Persistent revenue and profit deteriorationRepeated revenue declines and a shift from positive profitability in 2021–2022 to deeply negative operating and net margins weaken the company’s earnings base. Without a sustained recovery in sales, fixed research, selling, and administrative costs can continue to absorb gross profit.

Symbio Pharmaceuticals Limited (4582) vs. iShares MSCI Japan ETF (EWJ)

-75%-50%-25%0%25%50%75%100%JP:4582-33.01%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 3.80B
Dividend Yield
―
Average Volume (3M)
4.50M
Price to Earnings (P/E)
-0.8
Beta (1Y)
-0.30
Revenue Growth
-30.58%
EPS Growth
6.93%
Country
Japan
Employees
91
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Symbio Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers...

Symbio Pharmaceuticals Limited Financial Statement Overview

Summary

Fundamentals are in distress across all three statements. Revenue collapsed 28% in FY2025 to ¥1.3B (down over 85% from the ¥10B 2022 peak), producing a ¥4.8B net loss and a -365% net margin despite healthy 72% gross margins. Equity has eroded to ¥1.3B from ¥4.2B a year earlier, with ¥2B of new debt (1.56x debt/equity) after years of being debt-free, and ROE at -375%. Operating and free cash flow of -¥4.6B exceeds the entire equity base, implying the cash cushion could be exhausted within a year absent dilutive financing or restructuring.

Income Statement

15Very Negative

Balance Sheet

28Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.06B1.31B2.45B5.59B10.01B8.25B
Gross Profit778.13M947.34M1.87B4.41B7.60B5.80B
EBITDA-6.05B-4.60B-3.78B-714.00M2.06B1.11B
Net Income-6.09B-4.78B-3.83B-1.96B1.18B2.03B
Balance Sheet
Total Assets932.36M3.87B4.97B8.17B17.43B15.18B
Cash, Cash Equivalents and Short-Term Investments253.99M2.88B3.96B6.52B6.28B3.86B
Total Debt800.00M1.98B0000
Total Liabilities2.23B2.60B770.77M8.14B8.92B8.43B
Stockholders Equity-1.30B1.27B4.20B7.21B8.51B6.75B
Cash Flow
Free Cash Flow0-4.58B-3.44B-427.48M1.57B76.20M
Operating Cash Flow0-4.58B-3.42B-194.69M1.61B140.04M
Investing Cash Flow0-75.92M-3.96M-376.70M-47.13M-70.85M
Financing Cash Flow03.62B708.47M680.16M627.99M-71.92M

Symbio Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price69.00

Price Trends

50DMA55.70Positive
100DMA62.06Positive
200DMA80.33Negative

Market Momentum

MACD4.82Negative
RSI57.82Neutral
STOCH64.49Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Positive. The current price of 69.00 is above the 20-day moving average (MA) of 57.05, above the 50-day MA of 55.70, and below the 200-day MA of 80.33, indicating a neutral trend. The MACD of 4.82 indicates Negative momentum. The RSI at 57.82 is Neutral, neither overbought nor oversold. The STOCH value of 64.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4582.

Symbio Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4582 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4574JP:457469NeutralJPY 12.72B29.01―1.35%13.72%-50.46%
JP:4512JP:451252NeutralJPY 10.03B53.95―1.25%23.41%149.71%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4586JP:458648NeutralJPY 5.71B-6.72――-81.42%36.56%
JP:4539JP:453946NeutralJPY 5.70B-11.69―3.25%0.31%-194.72%
JP:4597JP:459739UnderperformJPY 7.10B-8.55-53.06%―109.82%61.98%
JP:4582JP:458237UnderperformJPY 7.87B-0.76――-30.58%6.93%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:4582JP:4597JP:4512JP:4539JP:4574JP:4586Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4582 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4582Symbio Pharmaceuticals Limited69.00-34.00-33.01%
JP:4597Solasia Pharma KK26.00-5.00-16.13%
JP:4512Wakamoto Pharmaceutical Co., Ltd.280.006.312.30%
JP:4539Nippon Chemiphar Co., Ltd.1540.0059.184.00%
JP:4574Taiko Pharmaceutical Co., Ltd.244.00-50.00-17.01%
JP:4586Medrx Co., Ltd.107.00-5.00-4.46%

Symbio Pharmaceuticals Limited Corporate Events

SymBio Pharmaceuticals Swings to Deep Negative Equity as Losses Mount in 2026

Oct 29, 2026

SymBio Pharmaceuticals reported a sharp deterioration in its financial position for the first nine months of 2026, with net sales dropping 25.6% year-on-year to ¥722 million and losses deepening as operating profit fell to a ¥4,870 million deficit. T...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026